[HTML][HTML] Selective estrogen receptor modulators (SERMs) and selective estrogen receptor degraders (SERDs) in cancer treatment
HK Patel, T Bihani - Pharmacology & therapeutics, 2018 - Elsevier
Breast cancer is the most frequently diagnosed cancer in women, with estrogen receptor
positive (ER+) breast cancer making up approximately 75% of all breast cancers diagnosed …
positive (ER+) breast cancer making up approximately 75% of all breast cancers diagnosed …
Drug repurposing in cancer
L Sleire, HE Førde, IA Netland, L Leiss, BS Skeie… - Pharmacological …, 2017 - Elsevier
Cancer is a major health issue worldwide, and the global burden of cancer is expected to
increase in the coming years. Whereas the limited success with current therapies has driven …
increase in the coming years. Whereas the limited success with current therapies has driven …
[HTML][HTML] The clinician's guide to prevention and treatment of osteoporosis
MS LeBoff, SL Greenspan, KL Insogna… - Osteoporosis …, 2022 - Springer
Osteoporosis is the most common metabolic bone disease in the USA and the world. It is a
subclinical condition until complicated by fracture (s). These fractures place an enormous …
subclinical condition until complicated by fracture (s). These fractures place an enormous …
[HTML][HTML] Clinician's guide to prevention and treatment of osteoporosis
F Cosman, SJ de Beur, MS LeBoff, EM Lewiecki… - Osteoporosis …, 2014 - Springer
Abstract The Clinician's Guide to Prevention and Treatment of Osteoporosis was developed
by an expert committee of the National Osteoporosis Foundation (NOF) in collaboration with …
by an expert committee of the National Osteoporosis Foundation (NOF) in collaboration with …
[HTML][HTML] Selective oestrogen receptor modulators in prevention of breast cancer: an updated meta-analysis of individual participant data
Background Tamoxifen and raloxifene reduce the risk of breast cancer in women at elevated
risk of disease, but the duration of the effect is unknown. We assessed the effectiveness of …
risk of disease, but the duration of the effect is unknown. We assessed the effectiveness of …
[HTML][HTML] Atypical hyperplasia of the breast—risk assessment and management options
LC Hartmann, AC Degnim, RJ Santen… - … England Journal of …, 2015 - Mass Medical Soc
Atypical Hyperplasia of the Breast — Risk Assessment and Management Options | NEJM
Skip to main content NEJM Group Follow Us Facebook Twitter Instagram YouTube LinkedIn …
Skip to main content NEJM Group Follow Us Facebook Twitter Instagram YouTube LinkedIn …
[HTML][HTML] Molecular mechanisms and clinical management of cancer bone metastasis
M Wang, F Xia, Y Wei, X Wei - Bone research, 2020 - nature.com
As one of the most common metastatic sites of malignancies, bone has a unique
microenvironment that allows metastatic tumor cells to grow and flourish. The fenestrated …
microenvironment that allows metastatic tumor cells to grow and flourish. The fenestrated …
Postmenopausal hormone therapy: an Endocrine Society scientific statement
Objective: Our objective was to provide a scholarly review of the published literature on
menopausal hormonal therapy (MHT), make scientifically valid assessments of the available …
menopausal hormonal therapy (MHT), make scientifically valid assessments of the available …
Effects of tamoxifen vs raloxifene on the risk of developing invasive breast cancer and other disease outcomes: the NSABP Study of Tamoxifen and Raloxifene (STAR) …
VG Vogel, JP Costantino, DL Wickerham, WM Cronin… - Jama, 2006 - jamanetwork.com
ContextTamoxifen is approved for the reduction of breast cancer risk, and raloxifene has
demonstrated a reduced risk of breast cancer in trials of older women with osteoporosis …
demonstrated a reduced risk of breast cancer in trials of older women with osteoporosis …
Medication use to reduce risk of breast cancer: US preventive services task force recommendation statement
DK Owens, KW Davidson, AH Krist, MJ Barry… - Jama, 2019 - jamanetwork.com
Importance Breast cancer is the most common nonskin cancer among women in the United
States and the second leading cause of cancer death. The median age at diagnosis is 62 …
States and the second leading cause of cancer death. The median age at diagnosis is 62 …